Novel therapies focused on the high-density lipoprotein particle

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Metabolic Research

Background:

• Cardiovascular disease (CVD) poses a significant health burden despite existing low-density lipoprotein-cholesterol (LDL-C) therapies.
• Residual CVD risk necessitates the development of novel therapeutic strategies.
• High-density lipoprotein-cholesterol (HDL-C) levels show an inverse correlation with CVD risk, prompting research into HDL-C-raising therapies.

Purpose of the Study:

• To provide a comprehensive review of pharmaceutical strategies targeting HDL metabolism.
• To cover HDL-targeted therapies in both early development and late-stage clinical trials.

Main Methods:

• Review of prospective epidemiological studies on HDL-C and CVD risk.
• Analysis of clinical trial data for various HDL-targeting interventions.
• Examination of targets within HDL metabolism, including CETP inhibitors, apoA1-based compounds, and others.

Main Results:

• Initial cholesteryl ester transfer protein (CETP) inhibitors showed limited success or increased mortality, though some are still in Phase III trials.
• Emerging HDL-based interventions like apolipoprotein A1 mimetics, ABC-transporter upregulators, and others show significant future potential.
• Various targets in HDL metabolism are being explored for therapeutic benefit.

Conclusions:

• HDL-targeted therapies represent a promising avenue for managing residual CVD risk.
• Further research and clinical trials are essential to validate the efficacy and safety of these novel HDL-based interventions.
• Developing effective HDL-increasing therapies could significantly impact cardiovascular health outcomes.